Various antiplatelet agents with different modes of action are utilized to prevent brain and heart infarction.
Multiple antiplatelet options remain in use for infarction prevention; leaves open optimal agent selection pending comparative trials.
White platelet-fibrin thrombi often form on roughened endothelial surfaces and unstable arterial plaques. Agents that reduce the tendency of platelets to aggregate, agglutinate, and secrete and to attach to endothelial surfaces have been explored as agents that prevent brain and heart infarction. Aspirin, ticlopidine, clopidogrel, dipyridamole, cilostazol, and glycoprotein llb/llla inhibitors are all used now and have various different modes of action and functions.
No takes yet. Share an insight, caveat, or question.
Louis R. Caplan (2006) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: